Last reviewed · How we verify
NCT07355062
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Veverimer in Adults With CKD and Metabolic Acidosis (The REVIVE Study)
Phase 3 trial testing Veverimer in CKD in 150 participants. Currently enrolling.
1 June 2027
Quick facts
| Lead sponsor | Renibus Therapeutics, Inc. |
|---|---|
| Phase | Phase 3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 150 |
| Start date | 13 January 2026 |
| Primary completion | 1 June 2027 |
| Estimated completion | 1 June 2027 |
| Sites | 19 locations across United States |
Drugs / interventions tested
- Veverimer — full drug profile →
- Placebo
Conditions studied
- CKD — all drugs for CKD →
- Metabolic Acidosis — all drugs for Metabolic Acidosis →
Sponsor
Renibus Therapeutics, Inc. — full company profile →
Who can join
18 and older, any sex, with CKD or Metabolic Acidosis. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Efficacy of Veverimer by measuring change in serum bicarbonate concentration (SBC)
Time frame: Visits: Screening to Day 168 -
Efficacy of Veverimer in improving physical performance as assessed by the Sit-to-Stand 5 times test (STS5).
Time frame: Visits: Screening to Day 168
Sponsor's own description
The purpose of this 26 week study is is to evaluate the efficacy and safety of veverimer in treating adults with moderate-to-severe chronic kidney disease (CKD) and metabolic acidosis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07355062
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for CKD
Currently open trials in the same condition.
- NCT07312981 — The CPH-MBD Cohort Dietary Substudy - Comparison of Methods for Dietary Registrations · recruiting
- NCT06892249 — Suitability of Two Flavours of a High-energy, Low-protein Formula (Renalive® LP) in Chronic Kidney Disease Stage 3b-5 Ou · NA · recruiting
- NCT07062952 — Kidney-protective Intervention With Salt Substitute After Kidney Tumor Surgery · NA · recruiting
- NCT07182942 — The Effect and Mechanism of Xiqing Regulating Intestinal Homeostasis on Drug Efficacy of Chronic Kidney Disease · Phase 4 · recruiting
- NCT06775028 — Integrated Approach in Frail Older People with Atrial Fibrillation · NA · recruiting
Other Renibus Therapeutics, Inc. trials
Trials by the same sponsor.
- NCT07009340 — Retrospective Observational Study of Patients Who Have Undergone Coronary Artery Bypass Graft (CABG) and/or Cardiac Valv · active not recruiting
- NCT06021457 — Effect of RBT-1 on Reducing the Risk of Post-Operative Complications in Subjects Undergoing Cardiac Surgery · Phase 3 · completed
- NCT06092970 — An Evaluation of Patient Reported Outcomes and Clinical Outcomes · active not recruiting
- NCT04564833 — Effect of RBT-1 on Preconditioning Response Biomarkers in Subjects Undergoing CABG and/or Cardiac Valve Surgery · Phase 2 · completed
- NCT04364763 — A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study) · Phase 2 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07355062 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Renibus Therapeutics, Inc.
- Last refreshed: 29 May 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07355062.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing